A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Clinipace, Inc.
Start Date
February 1, 2016
End Date
January 31, 2026
Administered By
Duke Cancer Institute
Awarded By
Clinipace, Inc.
Start Date
February 1, 2016
End Date
January 31, 2026